Which diabetes medication is most suitably paired with its adverse effect?

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor commonly used in the management of type 2 diabetes. One of the well-documented adverse effects associated with this class of medication is an increased risk of urinary tract infections (UTIs). The mechanism behind this side effect is related to the way SGLT2 inhibitors work: they promote the excretion of glucose in the urine, and the presence of glucose can provide a conducive environment for the growth of bacteria, thereby increasing the likelihood of UTIs.

This connection makes the pairing of canagliflozin with urinary tract infections appropriate, reflecting a recognized and significant adverse effect that healthcare providers monitor when prescribing this medication. Understanding these associations helps clinicians anticipate possible complications and manage patient care effectively.